CRSP - CRISPR Therapeutics AG (CRSP) Presents at Citi 2024 Virtual Oncology Leadership Summit Conference (Transcript)

2024-02-21 18:04:03 ET

CRISPR Therapeutics AG (CRSP)

Citi 2024 Virtual Oncology Leadership Summit Conference

February 21, 2024, 01:00 PM ET

Company Participants

Samarth Kulkarni - Chairman and Chief Executive Officer

Conference Call Participants

Yigal Nochomovitz - Citigroup

Presentation

Yigal Nochomovitz

All right. Welcome back, everyone, to the next session of Citi's Virtual Oncology Leadership Summit. I'm Yigal Nochomovitz, one of the biotech analysts here at Citigroup. Remember if you have questions for Sam Kulkarni, the CEO of CRISPR, who's our next speaker, just e-mail me, and I will be able to just check the e-mail and relate the questions.

So Sam, again, thank you so much for taking the time to speak with us and an incredibly busy schedule. Obviously, everyone is pretty familiar with your story. But still, I think it would be helpful just to set the scene at a very high level. What are the long-term goals of the company? What are some of the key priorities for 2024? And what should people be watching for? Thanks.

Samarth Kulkarni

Yes. Thank you, Yigal, for having us at this conference. I always enjoy these fireside chats with you, whether it's virtual or in person. And it's an important time to do it given the stage of the company. We're almost a decade into starting the company when we -- since we started the company, and we're here where. We've gotten the first CRISPR drug approved in the world, which is a remarkable achievement.

But we've also put our portfolio in such a strong position to parlay this initial success into something that could be multi-asset, multi-therapeutic area with different growth levers that could get us to becoming a sustainable company in the not-too-distant future. I was reading an article today about the $100 billion club and how Vertex and Regeneron are part of the $100 billion club but they both were started in 1988 and '89, it takes 30-plus years or longer to get to that kind of level and it took Genentech just as long, maybe a little bit shorter.

But hopefully, we can be on the same trajectory with CRISPR and do it in an even faster timescale, just like we've been much faster in getting our first drug approved relative to some other companies that have installed works in the biotech space.

So for us, overall, the mission remains the same, which is to create a great company, great biotech company that's getting drugs to the clinic, but also through the clinic to patients to help patients with severe diseases across a number of different therapeutic areas....

For further details see: